Spectrum Pharmaceuticals (SPPI) 10-K2016 FY Annual report

Filed: 14 Mar 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Affymetrix, Albany, Alkeran, allergic, AMAG, Amphastar, Anderson, anemia, array, arrest, ASCT, AstraZeneca, ATM, Ayeni, baby, belonging, Bendeka, Betadex, bioequivalence, blockage, bowel, breakdown, breath, bundle, cardiopulmonary, CHOP, chromosome, Codification, commensurate, complication, concept, Congressional, constipation, CR, creatinine, CRi, CRO, cyber, declaratory, dehydration, deliverable, deploy, dermatologic, distraction, docetaxel, dyspnea, eleven, Enanta, engraftment, espionage, Ether, executory, Exon, extravasation, fatigue, FBR, febrile, feet, fever, gastrointestinal, Genomic, Glen, Hartsock, Harvard, hematochezia, hepatic, hepatotoxicity, hundred, hypersensitivity, implied, infection, infertility, Infinity, inflationary, intraperiod, IRC, IRS, Istodax, IWC, kidney, leakage, malware, manifested, MD, median, membrane, Merrimack, mg, MiMedx, MLV, mouth, myeloablation, myelodysplastic, nausea, nerve, Neulasta, neurologic, neuropathy, neutrophil, obstruction, Olutayo, overstock, Pacific, pancytopenia, Pernix, persuasive, platelet, pneumonia, pose, potent, privacy, prolonged, push, pyrexia, QAPZOLA, reaction, reclassified, remission, remitted, reoccur, respiratory, retrospective, retrospectively, Sanofi, sensitive, Sodium, square, standalone, stomach, store, stream, subtype, Sulfobutyl, Supplementary, suppression, syndrome, TC, theft, throat, thrombocytopenia, tissue, transmit, transparency, Trump, Twenty, unborn, unclear, unconfirmed, unearned, University, unrealizable, unresolved, unspecified, unwound, Vanda, vigorously, vomiting, Wainwright, weekly, Workshop, xiv

Removed: abandonment, accessibility, acetylation, alisertib, announcement, arrive, Astra, BioMarin, bore, cancellation, chromatin, collaborating, concentration, consulting, CTCL, cytotoxic, declined, distinct, enable, enjoin, eoquin, explored, exploring, Fargo, FIFO, flower, GCSF, gene, generation, Genta, Handok, importantly, injunctive, Innopharma, Interbank, intracellular, involuntary, joined, lender, LIBOR, London, lowest, margin, misleadingly, Mylan, optimistic, predominant, preference, putative, ratio, region, renazorb, repaid, repeated, resistance, responding, retention, retired, revolving, RFC, safely, STAR, strong, subpoena, sustainable, transcription, travel, Treanda, Turning, unamortized, unconverted, winding, Zeneca

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

SPPI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Spectrum Pharmaceuticals, Inc. (the “Company”), hereby certifies, to such officer’s knowledge, that:

(i) the accompanying Annual Report on Form 10-K of the Company for the year ended December 31, 2016 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 14, 2017

/s/ KURT A. GUSTAFSON

Kurt A. Gustafson

Executive Vice President and Chief Financial Officer

This certification accompanies this Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.